Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
YARDLEY, Pa., Feb. 15, 2018 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2018 RBC Capital Markets Healthcare Conference February 21, 2018, at 3:05 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event.
About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has corporate offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com.
Optinose Investor Contact
Jonathan Neely
[email protected]
267.521.0531
Optinose Media Contact
Kate Traynor, Sloane & Company
[email protected]
212.446.1871
